With a degree in chemical engineering and intern experience at one of the world’s largest pharmaceutical companies, Vivian Tian, an Associate at Rothwell Figg, assists companies in the biologic, chemical, and pharmaceutical industries with patent prosecution and patent litigation matters.
Ms. Tian was previously a summer associate at Rothwell Figg where she assisted litigation teams in researching legal matters and preparing for client meetings and conducted patent landscape reviews for provisional patent applications. She spent another summer of law school at a law firm in South Carolina where she prepared instruction letters to foreign associates in response to international patent office actions and researched and drafted claims in various fields of art. Her experience also includes time at the Google Legal Summer Institute as a Google Legal Scholar where she performed hands-on claim analysis for computer science patent applications; Boehringer Ingelheim as a Summer Intern where she conducted research in the field of cellular biology; and the Johnson Group at MIT as an undergraduate researcher where she researched surface modification methods.
Ms. Tian received her J.D. from The George Washington University Law School. She was an associate editor at the AIPLA Quarterly Journal, a member of the Asian Pacific American Law Student Association, and a member of the Mock Trial Board. During the 1L Mock Trial Competition she was a semi-finalist. She earned her S.B. in chemical engineering with a minor in biology from the Massachusetts Institute of Technology (MIT). She is fluent conversationally in Mandarin Chinese.
This article, originally published on 12/27/2021, was updated on 1/12/2022 and republished on 1/13/2022 to include information that was omitted in error, beginning after “Conclusions and Outlook”.
In Part I of this post, we provided an update on three lead pioneers in the mRNA IP space, Moderna, BioNTech and CureVac. In this post we profile Sanofi, Arcturus, eTheRNA and other mRNA companies and offer conclusions. Sanofi (NASDAQ: SNY), headquartered in Paris, FR, acquired mRNA pioneer Translate Bio in September 2021 for approximately $3.2 billion and mRNA startup Tidal Therapeutics in April 2021 for approximately $470 million. With its acquisition of Translate alone, Sanofi obtained an mRNA pipeline of nine candidates (two in the clinic), hundreds of patents, and undoubtedly valuable mRNA-based technical and regulatory know-how.
In April of this year, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. In this post (Part I), we provide a 2021 year in review update on mRNA pioneers Moderna, BioNTech and CureVac, and in Part II, we profile Sanofi and other companies in the mRNA space and offer additional conclusions and outlook for 2022 and beyond.